XLock Biosciences’ CEO Dr. William Clarke has been awarded a Direct to Phase II SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in the amount of $1.99M for his project titled “Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation”.

XLock Biosciences’ CEO Dr. William Clarke has been awarded an SBIR Phase I grant from the NIH National Heart, Lung, and Blood Institute in the amount of $259,613 for his project titled “Development of an engineered CCL20 as a therapeutic molecule for chronic graft-versus-host disease”.

XLock Biosciences has been awarded an SBIR/STTR matching grant from the Wisconsin Economic Development Corporation in the amount of $100,000.

Following their success with the Phase I study, XLock Biosciences’ Senior Scientific Advisor Dr. Anthony Getschman and Founder Dr. Brian Volkman have been awarded an SBIR Phase II grant from the NIH National institute of Arthritis and Musculoskeletal and Skin Diseases in the amount of $1,685,879 for their project titled “Development of an engineered CCL20 protein as a lead therapeutic molecule for Psoriasis”.

XLock Biosciences’ Senior Scientific Advisor Dr. Anthony Getschman and Founder Dr. Brian Volkman have been awarded an SBIR Phase I grant from the NIH National institute of Arthritis and Musculoskeletal and Skin Diseases in the amount of $224,999 for their project titled “Development of an engineered CCL20 protein as a lead therapeutic molecule for Psoriasis”.